User login
Key clinical point: Given the chronic nature of the disease, antipsoriasis biologics are associated with low median persistence, which is relatively high for interleukin inhibitors vs tumor necrosis factor inhibitors and may change over time.
Major finding: Overall, the median persistence was 23.8 months (95% CI, 21.6-26.2), longest for ustekinumab (49.3 months [95% CI, 38.0-59.1]) and shortest for etanercept (16.3 months [95% CI, 14.5-19.0]). An approximately 50% decrease in the median persistence for ustekinumab, from 62.3 (95% CI, 45.6-∞) months to 32.7 (95% CI, 21.2-49.3) months, occurred between 2010-2011 and 2014-2016.
Study details: The data come from a retrospective cohort study consisting of 2,292 adult patients with psoriasis who had received at least 1 biologic between 2010 and 2018.
Disclosures: The study was sponsored by LEO Pharma. Levin L-Å declared receiving consulting fees from various sources including LEO Pharma, and some of the authors are employees of LEO Pharma.
Source: Schmitt-Egenolf M et al. Dermatol Ther (Heidelb). 2021 Oct 14. doi: 10.1007/s13555-021-00616-7.
Key clinical point: Given the chronic nature of the disease, antipsoriasis biologics are associated with low median persistence, which is relatively high for interleukin inhibitors vs tumor necrosis factor inhibitors and may change over time.
Major finding: Overall, the median persistence was 23.8 months (95% CI, 21.6-26.2), longest for ustekinumab (49.3 months [95% CI, 38.0-59.1]) and shortest for etanercept (16.3 months [95% CI, 14.5-19.0]). An approximately 50% decrease in the median persistence for ustekinumab, from 62.3 (95% CI, 45.6-∞) months to 32.7 (95% CI, 21.2-49.3) months, occurred between 2010-2011 and 2014-2016.
Study details: The data come from a retrospective cohort study consisting of 2,292 adult patients with psoriasis who had received at least 1 biologic between 2010 and 2018.
Disclosures: The study was sponsored by LEO Pharma. Levin L-Å declared receiving consulting fees from various sources including LEO Pharma, and some of the authors are employees of LEO Pharma.
Source: Schmitt-Egenolf M et al. Dermatol Ther (Heidelb). 2021 Oct 14. doi: 10.1007/s13555-021-00616-7.
Key clinical point: Given the chronic nature of the disease, antipsoriasis biologics are associated with low median persistence, which is relatively high for interleukin inhibitors vs tumor necrosis factor inhibitors and may change over time.
Major finding: Overall, the median persistence was 23.8 months (95% CI, 21.6-26.2), longest for ustekinumab (49.3 months [95% CI, 38.0-59.1]) and shortest for etanercept (16.3 months [95% CI, 14.5-19.0]). An approximately 50% decrease in the median persistence for ustekinumab, from 62.3 (95% CI, 45.6-∞) months to 32.7 (95% CI, 21.2-49.3) months, occurred between 2010-2011 and 2014-2016.
Study details: The data come from a retrospective cohort study consisting of 2,292 adult patients with psoriasis who had received at least 1 biologic between 2010 and 2018.
Disclosures: The study was sponsored by LEO Pharma. Levin L-Å declared receiving consulting fees from various sources including LEO Pharma, and some of the authors are employees of LEO Pharma.
Source: Schmitt-Egenolf M et al. Dermatol Ther (Heidelb). 2021 Oct 14. doi: 10.1007/s13555-021-00616-7.